ArticleProbiotics and antimicrobial proteins2026
Integration of Conjugated Linoleic Acid-Producing Probiotic Strains Having Anti-adipogenic Properties with Honey and Oyster Mushrooms for the Formulation of Non-dairy Probiotic Beverage.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conjugated linoleic acid (CLA) has been linked to various health benefits, including anti-cancer, anti-diabetic, and anti-obesity effects. Obesity, marked by abnormal fat deposition, increases the risk of metabolic disorders such as cardiovascular diseases and type-2 diabetes. Natural anti-adipogenic modulators with insulin sensitivity are one of the approaches to address the issue. In the present study, four distinct CLA-producing probiotic strains (Lacticaseibacillus paracasei LUL:01, Latilactobacillus curvatus LGM:16, Lactiplantibacillus paraplantarum LRJ1:09, and Enterococcus faecalis LJM:05) were assessed in vitro for their potential anti-adipogenic properties using 3T3-L1 preadipocytes. Out of four strains, LGM:16 inhibited lipid accumulation (100.27%), reduced intracellular triglyceride content (168.42, 168.16, and 153.66 mg/dL in a dose-dependent manner), and enhanced insulin sensitivity (32.23%) by increasing glucose uptake. Quantitative reverse-transcription polymerase chain reaction revealed the expression genes (PPARγ, C/EBPα, and GLUT-4) in LGM:16 strain. Consequently, LGM: 16 was used to develop a non-dairy probiotic formulation incorporating honey and Pleurotus ostreatus mushroom, ensuring a probiotic count above the minimum recommended level of 6 Log10 CFU/mL. Further, response surface methodology optimized probiotic beverage formulation to achieve favorable nutritional, good sensory profile, antioxidant, and anti-obesity activity, making it a promising candidate for health benefits.
Indexed as
Identifiers
40202588What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.